SCHEMBL6094477

SCHEMBL6094477

CCOc1ccc(CCNCCNc2cc(C)nc3c2nnn3-c2c(C)cc(C)cc2C)cc1OC

nearest known ligand 0.43

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
USP2 O75604 1/20 0.43
NPY1R P25929 1/20 0.41
CRHR1 P34998 2/20 0.41
PKM P14618 1/20 0.41
LMNA P02545 4/20 0.39
ALDH1A1 P00352 2/20 0.39
MAPK1 P28482 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
MAPT P10636 2/20 0.39
KMT2A Q03164 4/20 0.38
MEN1 O00255 3/20 0.38
HPGD P15428 2/20 0.38
TP53 P04637 4/20 0.38
POLB P06746 1/20 0.38
KDM4E B2RXH2 1/20 0.37
GAA P10253 1/20 0.37
THRB P10828 1/20 0.37
CALM1 P0DP23 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5793689 0.86 USP2 (0.44) USP2NPY1RPKMLMNAALDH1A1
SCHEMBL7042428 0.74 NPY1R (0.74) USP2NPY1RPKMLMNAALDH1A1
SCHEMBL6103775 0.72 CRHR1 (0.56) USP2CRHR1PKMLMNAMAPK1
SCHEMBL6095184 0.72 USP2 (0.40) USP2NPY1RPKMLMNAALDH1A1
SCHEMBL6094544 0.71 PKM (0.48) USP2NPY1RCRHR1PKMLMNA
SCHEMBL6093412 0.70 PTGDR (0.46) USP2PKMLMNAALDH1A1MAPK1
SCHEMBL6093643 0.68 NPY1R (0.51) NPY1RCRHR1ALDH1A1SMN1; SMN2MAPT
SCHEMBL7041881 0.68 NPY1R (0.61) NPY1RCRHR1LMNAALDH1A1MAPK1
SCHEMBL7783150 0.67 RECQL (0.38) NPY1RPKMLMNAALDH1A1MAPK1
SCHEMBL7791107 0.67 SMPD1 (0.44) LMNAALDH1A1SMN1; SMN2MAPTKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7074929-B2 Certain alkylene diamine-substituted heterocycles NEUROGEN CORP. (US) 2006-07-11 US disclosed
US-20040229870-A1 Certain alkylene diamine-substituted heterocycles NEUROGEN CORPORATION 2004-11-18 US disclosed
US-6696445-B2 NEUROPEPTIDE Y RECEPTOR ANTAGONISTS COMPRISING HETEROCYCLIC NITROGEN COMPOUNDS AND/OR PRODRUGS USED FOR PROPHYLAXIS OF EATING AND CARDIOVASCULAR DISORDERS NEUROGEN CORPORATION 2004-02-24 US disclosed
US-20030158197-A1 Certain alkylene diamine-substituted heterocycles NEUROGEN CORPORATION 2003-08-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030158197-A1 Certain alkylene diamine-substituted heterocycles NPY1R, NPY5R, NPY2R USP2 4015/4885NPY1R 1/4885CRHR1 16/4885
US-20040229870-A1 Certain alkylene diamine-substituted heterocycles NPY1R, NPY5R, NPY2R USP2 4081/4885NPY1R 1/4885CRHR1 14/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.